Phase 1/2/3

As Jasper Therapeutics completes Phase 2 enrollment for its novel IgAN therapy, we examine the structural shifts reshaping rare kidney disease treatment.

Pilatus Biosciences doses its first Hong Kong patient with PLT012, signaling a strategic shift toward metabolic immunotherapies and Asian clinical hubs.

As Novastra Therapeutics prepares to unveil Phase 1 data at ESMO, its supramolecular nanocloak could redefine how we treat checkpoint-resistant solid tumors.

Odyssey Therapeutics is testing a novel combination therapy for ulcerative colitis, aiming to break the therapeutic ceiling that limits current IBD treatments.

By targeting the genetic roots of BAG3 cardiomyopathy with a novel low-dose capsid, Affinia aims to solve gene therapy’s systemic toxicity bottleneck.

Asahi Kasei Therapeutics begins Phase 2a trials for AIC468, a pioneering RNA-splicing therapy aiming to solve a critical kidney transplant dilemma.

Margaret Mitchell explores how a German biotech's moss-grown protein could shift the paradigm in complement-mediated diseases from inhibition to restoration.

Equillium's Phase 1 trial of EQ504 in Australia signals a strategic shift in ulcerative colitis care, prioritizing targeted mucosal healing.

ViroMissile's intravenously delivered oncolytic virus, IDOV-2, shows early signs of stable disease in Phase I, hinting at a breakthrough for metastatic cancers.

Targeted protein degradation is breaking out of oncology. Monte Rosa’s latest Phase 1 readout tests if molecular glues can solve residual heart disease risk.

As diabetic amputations rise globally, a micro-cap biotech enters Phase 2a trials with a novel topical gel designed to physically destroy drug-resistant superbugs.

Heavy menstrual bleeding drives 600,000 surgeries a year. Hemab Therapeutics aims to replace invasive treatments with a once-a-month injection.

Fennec Pharmaceuticals unveils compelling trial data showing its therapy prevents permanent hearing loss in children undergoing life-saving chemotherapy.

A novel non-viral gene therapy shows early promise in treating Geographic Atrophy, targeting the root cause of iron overload to potentially reverse vision loss.

TOLREMO's successful Phase I trial for TT125-802 validates a novel strategy against NSCLC, offering new hope by targeting cancer's clever escape routes.

Xylo Bio's new drug for depression enters trials, betting it can rewire the brain without the hallucinogenic burden. Is this the future of mental healthcare?

As pharma giants dominate the obesity space with GLP-1 drugs, Corbus Pharmaceuticals is betting on a different mechanism. Will its upcoming data rewrite the rules?

PhenoNet completes a key trial milestone for its ALS therapy, not with a new molecule, but with a repurposed drug and a savvy regulatory and operational plan.

Encoded Therapeutics' ETX101 shows potential to not only halt seizures but also reverse developmental delays, suggesting a paradigm shift for rare neurological disorders.

New AI-powered analysis of Endeavor BioMedicines' taladegib shows significant lung volume gains, offering a glimmer of hope for reversing damage in IPF.